Nephrology · Chronic Kidney DiseaseTrial Updateclinicalmid-term

Boehringer Ingelheim Tests Vicadrostat with Empagliflozin in CKD Patients

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Boehringer Ingelheim4 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/25/2026, 12:32:12 PM

Assessment confidence: 60% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing clinical trial of vicadrostat in combination with empagliflozin represents a significant opportunity for Boehringer Ingelheim to strengthen its position in the nephrology market. Positive trial results could enhance their product portfolio and competitive standing against existing CKD therapies. Regulatory context from FDA (FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (6 high-relevance).

Strategic Assessment

Success in this trial may enhance Boehringer Ingelheim's portfolio and provide a competitive edge in CKD therapies. The strongest clinical anchor is A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease (ClinicalTrials.gov), entity match (boehringer ingelheim). In Nephrology · Chronic Kidney Disease, 6 regulatory and 2 competitive items passed relevance filtering for Boehringer Ingelheim.

Competitive Pressure

The most relevant competitive pressure comes from Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from V116 shows safety and immunogenicity in high-risk children for pneumococcal disease. This trial could position Boehringer Ingelheim favorably in the nephrology market, particularly against other treatments for CKD.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG) (FDA). Entity match (empagliflozin); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The outcomes of this trial will be critical for regulatory approval and labeling, influencing the future availability of this combination therapy in the market.

Key Risks

Elevated medium regulatory exposure for Boehringer Ingelheim could delay market entry or constrain labeling if agency review intensifies.
Competitive risk from Humanexa Signals (V116 shows safety and immunogenicity in high-risk children for pneumococcal disease) could weigh on Boehringer Ingelheim through competitive crowding and share erosion if follow-through weakens.

Key Opportunities

Success in this trial could lead to increased market share for Boehringer Ingelheim in the CKD segment, potentially translating into substantial revenue growth if the combination therapy proves effective.
Upside for Boehringer Ingelheim may improve if A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease (ClinicalTrials.gov) delivers favorable follow-through.
How we engage and involve patients and the public in our regulatory decision-making.
Success in this trial may enhance Boehringer Ingelheim's portfolio and provide a competitive edge in CKD therapies.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any announcements regarding efficacy and safety outcomes after the 4.5-month study period.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (empagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — EMPAGLIFLOZIN (ORIG)
FDAhigh relevance
Entity match (empagliflozin); Regulatory pathway relevance (nda)
FDA document
View source
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Opportunities for patients and the public to be involved in the work of the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Lessons Learned from our Roundtable with Rare Disease Advocates
FDAmedium relevance
Moderate corpus alignment
FDA document
View source

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
ClinicalTrials.govhigh relevance
Entity match (boehringer ingelheim)
FDA document
View source
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With Liver Disease Called NASH/MASH Who Have Cirrhosis
ClinicalTrials.govhigh relevance
Entity match (boehringer ingelheim)
FDA document
View source
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Anti-inflammatory Dietary Intervention in Patients With Type 2 Diabetes: A Randomized Controlled Trial
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
V116 shows safety and immunogenicity in high-risk children for pneumococcal disease
Humanexa Signalsmedium relevance
Moderate corpus alignment

Amino acid infusion and acute kidney injury after aortic surgery: a multicenter observational study with target trial emulation.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy of vunakizumab in patients with moderate-to-severe plaque psoriasis across diverse disease features: a post hoc analysis of a phase-III trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Wrist-Ankle Acupuncture on Postoperative Nausea and Vomiting Prophylaxis in High-Risk Female Patients: A Pragmatic, Randomized, Single-Blind, Sham-Controlled Trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of fecal microbiota transplantation and probiotics on the gut microbiome in antibiotic-treated septic patients: A pilot randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Impact of oliceridine versus sufentanil on postoperative nausea and vomiting in patients undergoing thyroid surgery: a prospective, double-blind, randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Oro-esophageal feeding for tracheostomized patients with severe traumatic brain injury: a randomized controlled trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Boehringer Ingelheim
empagliflozin
chronic kidney disease market

Commercial impact

medium

Success in this trial could lead to increased market share for Boehringer Ingelheim in the CKD segment, potentially translating into substantial revenue growth if the combination therapy proves effective.

Regulatory impact

medium

The outcomes of this trial will be critical for regulatory approval and labeling, influencing the future availability of this combination therapy in the market.

What to watch

Monitor trial results and any announcements regarding efficacy and safety outcomes after the 4.5-month study period.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.